更新于：2024-05-01
Penicillin G Potassium
青霉素钾
更新于：2024-05-01
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C16H18N2O4S |
InChIKeyJGSARLDLIJGVTE-MBNYWOFBSA-N |
CAS号61-33-6 |
查看全部结构式(2)
关联
8
项与 青霉素钾 相关的临床试验评价APL-1202片对转运体OAT3底物青霉素钠人体内药代动力学影响的临床试验
Comparison of Intravenous Co-amoxiclav Versus Benzyl Penicillin in Children With Severe Tonsillitis
Neonatal and Paediatric Pharmacokinetics of Antimicrobials study - NAPPA (version 1.0)
100 项与 青霉素钾 相关的临床结果
登录后查看更多信息
100 项与 青霉素钾 相关的转化医学
登录后查看更多信息
100 项与 青霉素钾 相关的专利（医药）
登录后查看更多信息
215
项与 青霉素钾 相关的文献（医药）2024-01-01Journal of equine veterinary science
Equine fecal microbiota response to short term antibiotic administration.
Article
作者: J L Parker ; A Page ; O Jacob ; V Stanton ; B Davis ; M Flythe ; E N Adam
Though generally safe, research continues to demonstrate negative side effects of antibiotic administration on the gastrointestinal (GIT) microbiota across species. In horses, antibiotic associated diarrhea (AAD) is a life-threatening condition linked to the GIT microbiota. This study tested the hypothesis that short term antibiotic administration to healthy horses would negatively impact the fecal microbiota as measured by their ability to digest nutrients and through fecal shedding of disease-associated-bacteria. Twenty-four horses were assigned to one of four treatment groups: control (CO); potassium penicillin/gentamicin sulfate (KPG); ceftiofur crystalline free acid (EX); trimethoprim/sulfamethoxazole (SMZ); and treated for 4 days. Fecal samples were collected before treatment began (S0), the day after treatment conclusion (S5), and at 10, 14, 21, and 28 days after initiating treatment. Horses had highly individualized responses to antibiotic administration. All horses receiving antibiotics experienced significantly softer stool compared to controls. Lactobacillus spp. were dramatically reduced in all antibiotic treated S5 samples. Horses receiving antibiotics were significantly more likely to test positive for C. difficile or C. perfringens on fecal qPCR. In conclusion, response to antibiotic administration displays high inter-individual variability, but shows changes to the functions of fecal microbiota that may depend on the antibiotic used.
2023-06-21Pharmaceutics
Fabrication of Co-Assembly from Berberine and Tannic Acid for Multidrug-Resistant Bacteria Infection Treatment.
Article
作者: Tingting Zheng ; Huan Chen ; Chenyang Wu ; Jinrui Wang ; Mengyao Cui ; Hanyi Ye ; Yifan Feng ; Ying Li ; Zhengqi Dong
Long-term antibiotic use induces drug resistance in bacteria. This has given rise to the challenge of refractory infections, which have become a global health threat. Berberine (BBR) and tannic acid (TA) from plants exhibit promising antibacterial activities and may overcome antibiotic resistance. However, poor solubility and/or low penetration capability have limited their application. Carrier-free co-assembled nanocomposites composed entirely of BBR and TA exhibit improved or new properties and produce improved efficacy. Herein, we demonstrated that an ordered nanostructure could be spontaneously co-assembled by the solvent evaporation method using the two natural products. These co-assembled berberine-tannic acid nanoparticles (BBR-TA NPs) exhibited the best antibacterial effect compared with the corresponding physical mixture, pristine BBR, and some first-line antibiotics (benzylpenicillin potassium-BP and ciprofloxacin-Cip) against Staphylococcus aureus (S. aureus) and multidrug-resistant Staphylococcus aureus (MRSA). Even if the concentration of BBR-TA NPs was as low as 15.63 μg/mL, the antibacterial rate against S. aureus and MRSA was more than 80%. In addition to the synergistic effect of the two compounds, the antibacterial mechanism underlying the nanostructures was that they strongly adhered to the surface of the bacterial cell wall, thereby inducing cell membrane damage and intracellular ATP leakage. Furthermore, the in vivo wound healing effect of BBR-TA NPs was verified using an MRSA wound infection mouse model. The BBR-TA NPs achieved the best efficacy compared with BP and Cip. Moreover, cytotoxic and histopathological evaluations of mice revealed that the nanodrug had good biological safety. This facile and green co-assembly strategy for preparing nanoparticles provides a feasible reference for the clinical treatment of bacterial infection.
2023-04-22Animals : an open access journal from MDPI
Current Antimicrobial Use in Horses Undergoing Exploratory Celiotomy: A Survey of Board-Certified Equine Specialists.
Article
作者: Meagan Rockow ; Gregg Griffenhagen ; Gabriele Landolt ; Dean Hendrickson ; Lynn Pezzanite
In the past decade, there has been a considerable increase in the recognition of antimicrobial resistance in equine practice. The objective of this study was to survey the current clinical use of antimicrobials for a commonly performed surgical procedure (exploratory celiotomy) with the goal of understanding how recent literature and changes in microbial resistance patterns may have impacted antimicrobial selection practices. An electronic survey was distributed to veterinary professionals within the American College of Veterinary Internal Medicine (ACVIM) and the American College of Veterinary Surgery (ACVS). A total of 113 completed surveys were returned. Practitioners reported antimicrobials were most frequently given 30-60 min preoperatively (63.1%). Two antimicrobial classes were typically administered (95.5%), with gentamicin (98.2%) and potassium penicillin (74.3%) being the most common. Antimicrobials were typically not re-dosed intraoperatively (78.6%). Factors that affected overall treatment length postoperatively included resection (81.4%), bloodwork (75.2%), enterotomy (74.3%), fever (85.0%), incisional complications (76.1%), and thrombophlebitis (67.3%). The most common duration of antimicrobial use was 1-3 d for non-strangulating lesions (54.4% of cases) and inflammatory conditions such as enteritis or peritonitis (50.4%), and 3-5 d for strangulating lesions (63.7%). Peri-incisional and intra-abdominal antimicrobials were used by 24.8% and 11.5% of respondents, respectively. In summary, antimicrobial usage patterns were highly variable among practitioners and, at times, not concordant with current literature.
100 项与 青霉素钾 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 鼠咬热 | 批准上市 | 日本 更多 | |
| 感染 | 批准上市 | 美国 更多 | |
| 支气管炎 | 批准上市 | 日本 更多 | |
| 肺炎 | 批准上市 | 日本 更多 | |
| 梅毒 | 批准上市 | 日本 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 391 | 鹽製遞艱衊繭醖鬱鑰憲(蓋積夢築淵製齋憲顧構) = 淵網遞構製獵築遞憲鏇 膚憲廠餘製蓋齋網艱糧 (膚襯鑰顧蓋醖糧膚願夢 ) | - | 2016-04-05 | ||
壓鹹繭餘遞遞鬱蓋膚鬱(築構願餘蓋淵蓋範網糧) = 衊獵襯艱壓範艱選窪蓋 廠蓋網築範餘餘網窪膚 (繭簾鏇淵網鬱膚顧築淵 ) 更多 | |||||||
N/A | - | Corticosteroids | 鬱壓醖衊鏇製夢壓簾齋(膚網鏇鬱顧築願鏇廠鹹) = 積餘衊鹽餘艱鏇蓋鹹獵 齋淵醖繭衊糧鑰憲窪積 (艱壓壓觸廠餘選夢繭糧 ) | - | 2015-10-15 | ||
Interferons | 鬱壓醖衊鏇製夢壓簾齋(膚網鏇鬱顧築願鏇廠鹹) = 餘鑰製襯築範網襯廠鏇 齋淵醖繭衊糧鑰憲窪積 (艱壓壓觸廠餘選夢繭糧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用